Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
It shifts bacterial populations toward species associated with better metabolic health, increasing Bacteroidetes relative to Firmicutes
Table of contents Alveus Therapeutics Founded: 2024 Technology / disease area: Next-generation therapies for obesity and metabolic diseases Lead candidate: ALV-100 Alveus Therapeutics is a Philadelphia-headquartered metabolic disease biotech company with operations in Copenhagen, built around the idea that obesity drugs leave persistent gaps in durability, tolerability, and long-term adherence
Why is this important
Eghdami S, Eissazade N, Heidari Mokarar M, Boroon M, Orsolini L, Shalbafan M
Understanding the difference between research and pharmaceutical-grade compounds becomes critical in this context
And for a limited time, eligible patients can get a 30day supply for just $149 per month for the first four months
US$ 24.42
US$ 21.23
US$ 22.58
US$ 23.94
